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enough to require dialysis had a mortality of 57%. APACHERenal failure in the ICU: Comparison of the impact of acute
III predicted outcome very well in patients with no renal failurerenal failure and end-stage renal disease on ICU outcomes.
and patients with ARF at the time of scoring but underpre-Background. Acute renal failure (ARF) is associated with a
dicted mortality in those who developed ARF after ICU admis-persistent high mortality in critically ill patients in intensive care
sion and overestimated mortality in patients with ESRD.units (ICUs). Most studies to date have focused on patients
Conclusions. ARF is common in ICU patients and has a per-with established, intrinsic ARF or relatively severe ARF due
sistent negative impact on outcomes, although the majority ofto multiple factors. None have examined outcomes of dialysis-
ARF is not severe enough to require dialysis support. Thedependent chronic renal failure [end-stage renal disease (ESRD)]
mortality of patients with ARF from all causes is almost exactlypatients in the ICU. We examined the incidence and outcomes
similar to that noted using the same criteria two decades ago.of ARF in the ICU using a standard definition and compared
More profound ARF requiring dialysis continues to have anthese to outcomes of ICU patients with either ESRD or no
even greater mortality. Nevertheless, acute declines in renalrenal failure. We sought to determine the impact of renal dys-
function and/or loss of organ function on outcome. function are associated with a mortality that is not well ex-
Methods. We prospectively scored 1530 admissions to eight plained simply by loss of organ function. The majority of ARF
ICUs over a 10-month period for illness severity at ICU admis- patients who did not require dialysis still had a considerably
sion using the Acute Physiological and Chronic Health Evalua- higher mortality than the ESRD patients, all of whom required
tion (APACHE III) evaluation tool. Patients were defined as dialysis; while ARF patients who did require dialysis had a
having ARF based on the definition of Hou et al (Am J Med much higher morality than ESRD patients. APACHE III per-
74:243-248,1983) designed to detect significant measurable de- forms well and captures the mortality of patients with ARF at
clines in renal function based on serum creatinine. ESRD pa- the time of scoring. Development of ARF after scoring has a
tients were identified as being chronically dialysis-dependent profound effect on standardized mortality. We were unable
prior to ICU admission and the remainder had no renal failure. to identify a unique mortality associated with ARF, but the
Clinical characteristics at ICU admission and ICU and hospital presence of measurable renal insufficiency continues to be a
outcomes were compared between the three groups. sensitive marker for poor outcome.
Results. We identified 254 cases of ARF, 57 cases of ESRD
and 1219 cases of no renal failure for an incidence of ARF of
17%. Roughly half the ARF patients had ARF at ICU admis-
Acute renal failure (ARF) is a relatively common com-sion and the remainder developed ARF during their ICU stay.
plication of hospitalized patients and is associated withOnly 11% of ARF patients required dialysis support. ARF
patients had significantly higher acute illness severity scores a high morbidity and mortality [1]. ARF is a syndrome
than those with no renal failure, whereas patients with ESRD of multiple etiologies, usually approached diagnostically
had intermediate severity scores. ICU mortality was 23% for as pre-renal, post-renal, or intrinsic ARF. Implicitly,patients with ARF, 11% for those with ESRD, and 5% for
ARF is a measurable decline in renal function occurringthose with no renal failure. There was no difference in outcome
over a short period of time, often during the course ofbetween patients who had ARF at ICU admission and those
who developed ARF in the ICU. Patients with ARF severe a hospitalization. There is, however, no universally ac-
cepted definition of ARF, making it difficult to compare
different studies of therapy or outcome. Numerous re-
1 Current address: Richmond Nephrology Associates, Inc., Richmond, cent studies of relatively severe, usually intrinsic, ARFVirginia 23225.
primarily due to some form of acute tubular necrosis,
Key words: acute renal failure, dialysis, mortality, intensive care unit. have documented that outcomes are related both to se-
verity of ARF and also to the severity of co-morbidReceived for publication July 31, 2001
conditions [2–12]. A variety of illness stratification sys-and in revised form February 1, 2002
Accepted for publication April 9, 2002 tems have been employed to analyze the impact of over-
all co-morbidity on outcome of severe ARF [1, 3–7, 9–14] 2002 by the International Society of Nephrology
986
Clermont et al: Renal Failure in the ICU 987
Table 1. Criteria for identification of patients with prognosis than patients who had ARF at time of ICU
acute renal failure (ARF)
admission [7].
Creatinine mg/dL Interestingly, the criteria of Hou et al have never been
Baseline  applied to an ICU population to determine the overall
frequency and significance of measurable ARF in this1.9 0.5
2.0 to 4.9 1.0 population. We decided to re-examine the epidemiology
5.0 1.5 of ARF in the ICU and took advantage of an ICU popu-
 is the difference between the maximal and minimal values for serum creati- lation that was being prospectively scored for illness se-nine in the intensive care unit (ICU) adapted from Hou et al [15].
verity with the Acute Physiology and Chronic Health
Evaluation (APACHE III) system [11], an outcome pre-
dictor that has been described to be particularly well
and it is clear that co-morbidity has a major, possibly suited to ARF populations [7, 16]. We also took advan-
overriding, influence on mortality in severe ARF. For tage of a group of dialysis-dependent end-stage renal
example, isolated ARF, in or out of the intensive care disease (ESRD) patients in this population to examine
unit (ICU), has a much better prognosis that ARF associ- the impact of total absence of organ function in the
ated with multiple organ failure [6, 13, 14]. Isolated ARF absence of ARF. We know of no previous outcome data
occurring as a result of contrast nephrotoxicity following on such a population. We wished to examine the impact
routine procedures has an extremely low mortality. It of ARF from all causes with or without loss of renal
is not clear, therefore, what contribution loss of organ function on outcomes and compare this to the outcomes
function per se has on the outcome of ARF. of patients with no ARF or with ESRD.
A classic study by Hou et al [15] used a definition of
ARF based on graded changes in serum creatinine from
METHODSbaseline to describe the incidence and characteristics of
Study populationARF in a general hospital population. The criteria of
Hou et al are shown in Table 1. This definition of ARF The study population consisted of all patients admitted
would be expected to capture virtually all patients with to eight ICUs at the University of Pittsburgh Medical
measurably significant declines in renal function from Center (UPMC) over a 10-month period. The ICUs in-
any cause, pre-renal, post-renal or intrinsic. The overall cluded one medical ICU, one coronary care unit, three
incidence was about 5% with the majority having rela- general surgical ICUs, one trauma ICU, one neurologi-
tively mild ARF and very few having ARF severe enough cal/neurosurgical ICU, and one cardiothoraciac ICU.
to require dialysis. Nevertheless, the overall mortality The facility is a 703-bed urban tertiary care medical-
was still high (24.8%) and increased with severity of surgical complex, treating a broad spectrum of patients.
ARF and need for dialysis. In this early study, it was
Data collectionapparent that ARF may be associated with high mor-
tality even in the absence of severe organ failure. Re- APACHE III scores and the Acute Physiology Score
cently, studies by the Madrid Acute Renal Failure Group portion of APACHE III (APS3) were calculated from
[13, 14] and the French Study Group on Acute Renal data collected in the first 24 hours of ICU admission.
Failure [7] re-examined the epidemiology of ARF both All data were collected by four data collectors trained by
in overall hospital and ICU populations, using a some- APACHE Medical Systems, Inc., (McLean, VA, USA).
what more strict definition of ARF designed to capture Data collection and inter-rater reliability procedures were
more severe disease. Liano et al, for the Madrid ARF followed as previously described [11]. The electronic
group, defined ARF as a sudden increase in creatinine chart was reviewed for all patients. Serum creatinine
of greater than 2 mg % with previously normal creatinine values were documented during the ICU stay for each
[13]. Brivet et al, for the French ARF group [7], used a patient by review of the hospital computerized database.
creatinine greater than 3.5 mg % if previously normal or Values were noted at the time of ICU admission and
a doubling if abnormal. Neither group included patients discharge and throughout the hospital course. For the
purposes of ARF categorization, the baseline creatininewith baseline creatinine 3 mg %. The greater severity
of ARF required for inclusion in these studies resulted was equated with the minimal ICU creatinine value. If
no creatinine was obtained on the day of discharge, thein a higher proportion of patients requiring dialysis and
a higher overall mortality than that observed in the study value obtained within 24 to 48 hours was used. Since the
electronic records do not specifically keep track of allof Hou et al [15]. Once again, however, ARF had a sig-
nificant mortality and one group estimated a “corrected procedures, the frequency of dialysis treatments during
the hospitalization was verified by a review of the de-mortality due to ARF” of 26.7% [13, 14], with patients
who developed ARF in the ICU having an even worse tailed billing records.
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Table 2. Clinical patient characteristics (all values mean  SEM)Patient cohorts
ARF ESRD No ARFPatients with chronic renal failure on dialysis were
(N  254) (N  57) (N  1219)identified at the time of ICU admission (ESRD). Patients
Age years 591 582 591with acute renal failure (ARF) formed the second group
APACHE IIIa 642 643 421
analyzed and were stratified on the basis of baseline cre- APS3a 532 584 311
Temperature C 36.30.1 36.20.1 36.20.03atinine and change in creatinine, as defined previously
Systolic blood pressure mm Hga 1133 1306 1291[15]: 88% of admissions examined comprised the subgroup
Diastolic blood pressure mm Hga 542 584 661
with baseline serum creatinine1.9 mg/dL (Table 1) and Heart rate min1a 1122 1064 1001
Respirations min1a 211 212 190.3significant differences between the groups were not iden-
White blood cells 	109/La 14.50.6 10.70.7 12.70.3tified (data not shown). Three patients who did not meet
Abbreviations are: N, number of admissions; APACHE III, Acute Physiologi-ARF criteria but who were subsequently dialyzed on clini-
cal and Chronic Health Evaluation; APS 3, Acute Physiological Score.
cal grounds were included in the ARF group. Patients a By ANOVA single variant
who did not meet criteria for entry into either of these
groups and who did not receive dialysis by review of
records comprised the final group analyzed (no renal
tional (Cambridge, MA, USA) for analysis of variancefailure). The total number of patients and ICU admis-
(ANOVA) and t test. Results were considered significantsions were 1396 and 1530, respectively. The number of
when P 
 0.03.patients and admissions comprising each group were
245/254, 50/57, and 1101/1219 for ARF, ESRD, and no
renal failure, respectively. Each patient received a new
RESULTSAPACHE III score at the time of ICU admission and
multiple admissions for the same patient during the study Patient characteristics and outcomes
period were possible. To avoid confusion, data are pre- Patient clinical data for the three groups ARF, ESRD,
sented as ICU admissions, since each admission repre- and no renal failure are shown in Table 2. The incidence
sents a unique APACHE III score and risk for mortality. of ARF for the population at risk was 17.2%. This in-
All patients were managed by intensivists from the cluded all patients who had a significant deterioration
University of Pittsburgh. Patients in the coronary care of renal function during their ICU stay. This simple dis-
unit were managed by cardiologists, those in the medical tinction identified the group of patients who were differ-
intensive care unit by pulmonary/critical care, and all ent from the no renal failure group on a number of sig-
the remaining ICUs were staffed by intensivists from nificant measures (Table 2). The ARF patients had higher
the Department of Critical Care. All patients requiring mean APACHE III scores, higher acute physiology scores,
dialysis were evaluated and managed by the same group
and were relatively hypotensive, tachycardic, tachypneic,
of nephrologists at the University of Pittsburgh and indi-
and with higher white blood cell counts when comparedcations for renal replacement therapy (RRT) were con-
to the other patients groups. Similarly, ARF patients hadsidered similar for all patients with ARF as previously
both longer ICU lengths of stay and longer predicteddescribed [17]. RRT was either intermittent hemodialy-
ICU lengths of stay than those patients who did not de-sis or continuous venovenous hemodialysis (CVVHD).
velop ARF. Assuming each ICU admission places a pa-Hemodialysis was employed for hemodynamically stable
tient “at risk” for ICU death, the observed mortality forpatients, while CVVHD was used primarily for patients
ARF patients (23%) was greater than that for ESRDwho were either hemodynamically unstable or who re-
(11%) and no renal failure (5%) patients. Observed hos-quired such large amounts of intravenous therapy as to
pital mortality (which included ICU mortality) for ARFmake intermittent therapy impractical. Some patients
patients exceeded that noted for ESRD and no renal fail-received both modalities. ESRD patients were supported
ure patients. By these criteria, ARF patients were sicker,with RRT from the time of their admission to the hospital
required longer intensive care, had a higher predictedor ICU and generally initiated with a dialysis prescription
mortality, and even higher observed mortality than pa-and modality based on their outpatient therapy, but in
tients without ARF. Patients identified as having ESRDno case less than 12 hours of hemodialysis per week.
represented an interesting contrast to the ARF and noCVVHD was employed for ESRD patients in the ICU
renal failure groups as their clinical values and outcomeswho became hemodynamically unstable.
were intermediate between the two groups. Like the
Statistical analysis ARF patients, ESRD patients had high APACHE III
and APS3 scores, although without the hemodynamicData were expressed as mean  SEM analyzed us-
instability or leukocytosis seen in the ARF group. Theying the NCCS software package (Kaysville, UT, USA)
for 2 and Fisher’s Exact Test, and GreyMatter Interna- resembled the patients with no renal failure in their ac-
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Table 4. Renal failure in transplant patients (mean  SEM)Table 3. Clinical Outcomes
ARF ESRD No ARF ARF ESRD No ARF
(N  254) (N  57) (N  1219)
Patients/Admissions 30/34 13/16 36/48
Age yearsa 452 534 502ICU length of stay
daysa 111 51 40.1 APACHE IIIb 623 8010 493
APS3b 503 659 393ICU length of stay
(predicted) daysa 60.1 60.3 50.1 Scr (ICU admission) mg/dLb 3.30.7 5.80.7 2.10.2
Scr () mg/dLb 2.20.6 2.60.4 0.30.04ICU (predicted)a 0.1770.013b 0.1790.013b 0.0630.004b
ICU mortality ICU length of stay daysb 142 61 30.4
ICU length of stay(observed)c 59/254 (23%)c 6/57 (11%) 55/1219 (5%)
Standardized ICU (predicted) daysb 60.5 60.4 50.3
ICU death (predicted)b 0.180.04 0.260.09 0.080.02mortality 1.31 0.59 0.71
Hospital death Mortality 5/34 (15%) 1/16 (6%) 2/48 (4%)
Standardized mortality 0.82 0.24 0.52(predicted)a 0.2760.016b 0.2720.035b 0.1150.005b
Hospital mortality a P  NS by ANOVA single variant
(observed)c 86/254 (34%)c 8/57 (14%) 109/1219 (9%) b P 
 0.03 by ANOVA single variant
Standardized hospital
mortality 1.21 0.52 0.75
a By ANOVA single variant
b P  NS predicted vs. observed mortality (2 or Fisher’s Exact Test where
appropriate) between mortality for transplant groups compared to
c P 
 0.001 ARF vs. no renal failure by 2 the corresponding non-transplant patients in any of the
three groups.
Development of ARF in the ICUtual and standardized mortalities and ICU length of stay
The study of Brivet et al [7] suggested that outcome(Table 3).
is poor for patients who develop ARF in the ICU com-
Renal failure in transplant patients pared to those with ARF at ICU admission. The develop-
ment of ARF in the ICU might also influence the prog-Because transplant patients represent a potentially
nostic performance of admission APACHE scoring. Inunique population with respect to ARF outcomes [17]
order to estimate whether the development of ARF inand because they were not represented in the study of
the ICU had a different prognosis or varying relation toHou et al [15], we examined their outcomes separately.
admission APACHE score in terms of predicting out-We performed comparisons of clinical characteristics and
come when compared to prognosis and outcome of pa-outcomes for recipients of solid organ transplants with
tients with ARF at the time of admission, further sub-ARF, ESRD, and no renal failure (Table 4). The types
group analysis of the patients defined previously as havingand number of transplant admissions in each group
ARF was performed. To assess the impact of the devel-(ARF, ESRD, and no renal failure) were cardiac (7/0/6),
opment of ARF in the ICU, two groups were thus identi-pulmonary (16/2/14), liver (1/0/10), kidney (9/12/15), kid-
fied: those with admission creatinine values at baselineney-pancreas (0/2/0) liver-kidney (0/0/1), and bone mar-
(late ARF) and a separate group with admission creati-row (1/0/2), respectively.
nine values greater than their baseline, defining them asAge was not significantly different between the groups
ARF at admission (early ARF) (Table 5). Early ARFstudied. ESRD patients tended to have higher APACHE
patients tended to be older, with admission APACHEIII and APS3 scores than the other groups. Blood pres-
III and APS3 scores higher than late ARF patients. Earlysure, heart rate, respirations, and admission white blood
ARF patients tended to be more hypotensive, more ta-cell counts were not different between groups. ICU
chycardic, and tachypneic, although the difference inlengths of stay were longer in ARF patients. ICU lengths
respiratory rate was not significant. The difference be-of stay and observed mortality for transplant patients
tween peak and nadir creatinine values was greatest inwith ESRD were intermediate between those with ARF
early ARF patients, and ICU lengths of stay tended toand no renal failure, while standardized mortality for
be longer in late ARF patients. Observed mortality wasESRD patients trailed both groups, although there were
not different between the two groups suggesting a consis-no significant differences in observed mortality between
tent impact of ARF on outcome whenever it develops.the three groups, possibly due to the relatively small
However, standardized mortality was remarkably differ-number in each group. This pattern was similar to that
ent between the two subgroups. Standardized mortalityseen with non-transplant patients in that standardized
for patients with ARF on admission was near 1, sug-mortality was highest for ARF patients and lowest for
gesting that APACHE performed well in this group.ESRD patients, despite higher mean APACHE scores
Standardized mortality was more than doubled in pa-than those in the patients with no renal failure. Despite a
tients with normal renal function on ICU admission whotendency for mortality to be lower in transplant patients
(Tables 3 and 4), there were no significant differences subsequently developed ARF, suggesting development
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Table 5. Comparison of ARF in those with and without nitrogen at admission tended to be higher in non-survi-
renal dysfunction on ICU entry
vors (P 
 0.03). Maximal serum creatinine values be-
Late ARF Early ARF tween survivors and non-survivors were not different,
(N  118) (N  136) but there was a trend to greater differences in peak andDeaths, 30 Deaths, 29
nadir values in non-survivors. Fifty percent of ICU ARF
Agea 562 621
deaths occurred at an APACHE III score of greaterAPACHE IIIa 552 722
APS3a 452 602 than or equal to 73 [lethal score for 50% mortality
Temperature C b 36.30.1 36.30.1 (LS50) 73]. Eleven percent (28 of 254 patients) requiredSystolic blood pressure mm Hga 1184 1083
dialysis while in the ICU and an additional nine patientsDiastolic blood pressure mm Hgb 563 522
Heart rate min1a 1073 1163 required dialysis following discharge from the ICU, for
Respirations min1b 201 221 a total of 37 patients requiring dialysis after development
White blood cells 	109/Lb 14.50.9 14.50.7
of ARF (15%). Hospital mortality for those dialyzed inBlood urea nitrogen mg/dLa 221 473
Scr (ICU admission) 10.02 2.70.2 the ICU was 57% and hospital mortality for those dia-
Scr (nadir) mg/dLa 0.80.02 1.70.1 lyzed after transfer to the ICU (who did not receive
Scr (peak) mg/dLa 1.80.1 3.40.2 dialysis in the ICU) was 56%. Overall, the developmentScr (D) mg/dLa 1.10.1 1.80.1
Urinary output mLa 2815185 1843135 of ARF requiring dialysis indicated hospital mortality of
ICU length of stay daysb 131 101 57%. Dialysis was delivered as hemodialysis to 45%,
ICU length of stay (predicted) daysb 60.2 60.2
CVVHD to 36%, and the remaining 19% received bothICU death (predicted)a 0.120.02d 0.220.02c
Mortality (observed) 30/118 (0.25) 29/136 (0.21) modalities. For patients who received hemodialysis, treat-
Standardized mortality 2.08 0.95 ments were prescribed as 4-hour treatments with blood
N  number of admissions; unless otherwise noted, values represent mean  flows no less than 350 mL/min, except for initial hemodi-
SEM at first 24 hours of ICU admission.
alysis where lower flow rates sometimes employed ifa P 
 0.03 by one-tailed t test
b P  NS by one-tailed t test blood urea nitrogen 100 mg/dL. The interval between
c P  NS predicted vs. observed mortality (2 or Fisher’s Exact Test where
hemodialysis was 1.8  0.02 days. The relative propor-appropriate) (early ARF)
d P 
 0.03 by 2 predicted vs. observed mortality (late ARF) tion of modalities of RRT was similar to that we pre-
viously reported as is the mortality of patients requiring
dialysis support [17].
ARF from all causes not requiring ICU dialysis was
of ARF in the ICU had a negative impact on predicted
noted in 226 admissions. Assuming each ICU admission
outcome such that APACHE markedly under predicted places a patient at risk for death, ICU mortality for non-
mortality in this group. dialyzed patients with ARF was 20.4%; hospital mortal-
ity for this group of patients was 31.0%. Outcomes areSurvival analysis
not different if only the last ICU admission is considered
We wished to examine the characteristics of survivors for those with multiple ICU admissions in the ARF group.
and non-survivors in the three patient groups to deter- A similar analysis was carried out for survivors and
mine whether their characteristics differed (Table 6). We non-survivors who were dialysis dependent patients with
first performed intergroup analysis in which the survivors ESRD. Age was not significantly different between the
and non-survivors between groups were analyzed and two groups. Non-survivors had higher mean APACHE
compared. Age was not statistically different for survi- III and APS3 scores than survivors with ESRD. Al-
vors or non-survivors between groups. ESRD survivors though not statistically significant, non-survivors tended
had a significantly higher mean APACHE III and APS3 to have lower admission blood urea nitrogen and creati-
score than patients from the other study groups. ARF nine values, as well as peak creatinine values. Similar to
survivors tended to have longer ICU lengths of stay (10 ARF patients, non-survivors tended to have a greater
days). ARF non-survivors had lower APACHE III and difference in peak and nadir creatinine values, but this
APS3 scores than non-survivors from ESRD and those did not reach significance. ICU length of stay for non-
with no renal failure. ICU length of stay for ARF non- survivors tended to be longer than survivors (13 versus
survivors tended to be longer than non-survivors from 4 days). Fifty percent of ICU deaths occurred at APACHE
other groups. III scores of greater than or equal to 116 (LS50  116).
We next compared characteristics of the survivors and Dialysis support was initiated at admission for patients
non-survivors within groups (Table 6). Age was not dif- known to have ESRD. Patients were continued, if pos-
ferent between survivors and non-survivors of ARF. sible, on their outpatient modality. All but one patient
Non-survivors tended to have higher APACHE III and received hemodialysis. One patient was managed on peri-
APS3 scores, and ICU length of stay was longer in non- toneal dialysis and two patients received both hemodial-
survivors. Admission creatinine values were not different ysis and CVVHD. Dialysis was delivered on average
every 1.95  0.03 days for prescribed periods of no lessbetween survivors and non-survivors, but blood urea
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Table 6. Survivor and non-survivor characteristics (all values are means  SEM)
ARF CRF No Renal Failure
Survivors Non-survivors Survivors Non-survivors Survivors Non-survivors
Age years 581a 622a 582b 605 591b 612
APACHE III 592cd 803e 633c 11511 391c 945
APS 3 482cd 683e 533c 10311 291c 815
ICU length of stay days 101cd 153e 41c 139 40.1c 51
Blood urea nitrogen mg/dL 332c 434e 564b 4214 170.4c 273
Scr (ICU admission) mg/dL 1.90.1b 1.90.2e 7.20.6b 4.31.0 1.00.02c 1.30.1
Scr (nadir) mg/dL 1.20.1bd 1.30.1e 5.90.5b 3.71.1 0.90.02c 1.20.1
Scr (maximum) mg/dL 2.60.1b 3.10.2e 7.70.6b 6.21.0 1.00.02c 1.40.1
Scr () mg/dL 1.30.1c 1.80.2e 1.80.3b 2.50.9 0.10.004b 0.20.03
Abbreviations are: APS 3, Acute Physiological Score; Scr, serum creatinine; Scr (maximum), peak Scr while in ICU; Scr (), difference between maximal and minimal
values; urinary output, urine output in first 24 hours of ICU admission.
a Not significant for non-survivors between groups, ANOVA single-variant
b Not significant for survivors vs. non-survivors within group, t test
c P 
 0.03 survivors vs. non-survivors within group, t test
d P 
 0.03 for survivors between groups, ANOVA single-variant
e P 
 0.03 for non-survivors between groups, ANOVA single-variant
than 4 hours per treatment and blood flow rates of 350 rates of 0.21 to 1.38. The standard mortality rate for
ARF patients with APACHE III scores 130 exceededmL/min or greater. Just over half the dialysis treatments
per patient were delivered in the ICU and the frequency those of ESRD and no renal failure. Standard mortality
rates for patients generally trailed those of patients withof hemodialysis did not vary significantly after transfer
from the ICU. no renal failure, except in the APACHE III ranges of
When survival characteristics of patients with no renal 90 to 99 and 150.
failure were examined, age was not different between the
groups. Non-survivors exhibited higher mean APACHE
DISCUSSIONIII and APS3 scores than survivors. Non-survivors tended
The focus of this study was to describe the frequencyto have slightly longer ICU lengths of stay than survivor
and characteristics of all causes of ARF in the ICU and(5 versus 4 days). Admission creatinine and blood urea
determine the impact of acute deterioration of renalnitrogen and peak creatinine were higher in non-survi-
function, using a standard definition [15], on patient out-vors than survivors with no renal failure. The difference
come. This definition would be expected to capture allbetween peak and nadir creatinine values were insignifi-
patients with measurable decline in renal function fromcant. Fifty percent of ICU deaths occurred at an APACHE
pre-, post- or intrinsic renal failure [1]. We also soughtIII score of greater than or equal to 89 (LS50  89).
to compare the outcomes of ARF patients to those of
APACHE III ability to predict mortality in renal patients with dialysis-dependent chronic renal failure
failure patients and patients without renal dysfunction in the ICU. Fi-
nally, we evaluated the utility of a standardized predictorTo assess the ability of APACHE III to predict mor-
of outcome, APACHE III, as a prognostic indicator intality in patients with ARF and ESRD, we examined
the three groups. The overall incidence of acute renalAPACHE III deciles relative to observed, predicted,
failure in this study was 17.2%, with an observed mortal-and standardized mortality (Table 3 and Figures 1–4).
ity in ARF patients of 23% in the ICU. This is a higherPredicted mortality for ARF and ESRD patients in each
incidence than observed by Hou et al [15], but that studydecile appeared closely parallel. At scores less than 90,
was hospital-wide while ours was restricted to ICUsAPACHE III appeared to under-predict mortality in
where the incidence and potentially the severity of ARFARF patients (observed mortality was greater than
might be expected to be higher [13, 14]. Interestingly,predicted mortality), with an abrupt reversal of this
the mortality we noted was virtually identical to thepattern at scores90. APACHE III over-predicted mor-
overall mortality noted in the study of Hou et al [15],tality for ESRD patients with scores less than 109 (ob-
suggesting that ARF defined in this manner has a consis-served mortality was greater than predicted mortality).
tent effect on mortality. We also found that most ARFPredicted mortality for patients with no renal failure
defined in this manner did not actually require dialysisappeared to correlate well with observed mortality. Stan-
support, but that more severe ARF associated with thedardized mortality rates are shown in Figure 4. Standard-
need for dialysis support was associated with a higherized mortality rates for ESRD patients ranged from ap-
mortality. Our mortality was less than that observed byproximately 0.60 to 0.80 for APACHE scores 
150. No
renal failure patients showed standardized mortality Liano et al [13, 14] and Brivet et al [7] in their epidemio-
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Fig. 1. Acute Physiology and Chronic Health Evaluation (APACHE III) no renal failure patients. The relationship of observed mortality () to
mortality predicted by APACHE III () at each decile of APACHE III scores for all patients with no renal failure during the course of their
ICU stay. Fractional mortality is presented on the y axis and % mortality/100.
Fig. 2. Acute physiology and Chronic Health Evaluation (APACHE III) end-stage renal failure (ESRD) patients. The relationship of observed
mortality () to mortality predicted by APACHE III () at each decile of APACHE III scores for all patients with ARF. Fractional mortality
is on the y axis and % mortality/100.
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Fig. 3. Acute Physiology and Chronic Health Evaluation (APACHE III) acute renal failure (ARF) patients. The relationship between observed
mortality () to mortality predicted by APACHE III () for all dialysis-dependent ESRD patients. Fractional mortality is on the y axis and %
mortality/100.
Fig. 4. Standardized mortality. All patients in the study are displayed as a function of renal status and severity of APACHE III score. Symbols
are: (), acute renal failure (ARF); () end-stage renal disease (ERSD); ( ), no renal failure; N  number of admissions in decile
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logical studies of ARF. As we noted in the introduction,
however, the definitions of ARF in those studies were
designed to capture more severe ARF, and indeed they
had a higher percentage of patients requiring dialysis
support. The mortality we have noted is also lower than
that reported for select populations of established paren-
cyhmal acute tubular necrosis or ARF requiring dialysis
in the ICU [2–9]. When analysis is restricted to patients
requiring dialysis with ARF, the mortality is in excess
of 50%, similar to that noted in other studies and in
keeping with that noted in a recent retrospective evalua-
tion of ARF outcomes at this institution [17].
Defining ARF broadly as a deterioration of renal func-
tion from any cause led to the description of a large
subgroup of patients who differed significantly from the
population without renal failure. The ARF group had
higher mean APACHE III scores, greater hemodynamic
instability, longer ICU length of stay, and higher ICU
and hospital mortality than the patients with no renal
Fig. 5. Total ICU mortality for patients as a function of renal statusfailure. ICU and hospital mortality was roughly fourfold
and need for dialysis. Abbreviations are: NoRF, no renal failure; HD,higher in ARF patients than in no renal failure patients. hemodialysis; ARF, acute renal failure; ESRD, end-stage renal failure.
All this is consistent with the known negative impact of
ARF on outcomes in the ICU. Yet, only a small fraction
of these patients had ARF severe enough to require
comes of those patients who required RRT cannot bedialysis. In contrast, patients with ESRD were, by defini-
determined from this data, and optimum dialysis pre-tion, all dialysis dependent during their ICU stay. Al-
scription in ARF remains an area of controversy. ESRDthough their mean APACHE III scores were similar to
patients in the ICU received hemodialysis somewhatthe ARF subgroup, the actual outcomes of ESRD pa-
more frequently than the standard three times weeklytients in terms of ICU length of stay and mortality more
dialysis of outpatient centers, but formal analysis of di-closely resembled those patients with no renal failure.
alysis efficiency by either measurement of (dialysis dose)ESRD patients in the ICU represent a population who
Kt/V or urea reduction ratios was not performed. ARFrequire dialysis support but not in the clinical setting of
patients requiring RRT received hemodialysis more fre-ARF. It is interesting to compare the outcomes of ARF
quently than every other day, but not significantly morepatients with or without need for dialysis to those of non-
frequently than ESRD patients. ARF patients receivedARF patients also with or without need for dialysis. The
CVVHD more frequently than ESRD patients in themortality of ARF patients who did not require dialysis
ICU, since more than 50% of ARF patients requiringwas significantly higher (about fourfold) than that of no
RRT received CVVHD at some point during their ICUrenal failure patients, and the mortality of ARF patients
stay, while only 4% of ESRD patients received this mod-who required dialysis was significantly higher (also about
ality. This reflects primarily the greater hemodynamic in-fourfold) than that of critically ill ESRD patients who
stability of ARF patients, since, at our institution, CVVHDrequired dialysis (Fig. 5). These data suggest that the in-
is primarily used for patients who might not toleratecreased mortality associated with ARF is not a simple
standard hemodialysis [17].function of loss of organ function per se, but is related
It has been suggested that developing ARF in patientsto the clinical circumstances that lead to renal dysfunc-
already being treated for acute illness signals a negativetion. As supported by a review of prior epidemiological
course and that these patients might do poorer [7]. Instudies [7, 13, 14] and our data (Table 2), patients who
our study, just under half the patients who were identifieddevelop ARF are more hemodynamically unstable and
as having ARF during their ICU course had normal re-have greater degrees of leukocytosis than ICU patients
nal function at ICU admission. Patients with ARF atwho do not develop ARF. However, it is also clear from
admission (Table 5) were sicker by a number of clinicalthe ESRD mortality data that some element of mortality
measures and had significantly higher APACHE III scoresis clearly associated with loss of renal function, since
than did patients with normal renal function. The ICUESRD patients had a mortality twice that of patients
length of stay was prolonged by the development of ARFwith no renal failure. The development of ARF is a sen-
after ICU admission, but we were unable to demonstratesitive predictor of poor outcome.
The impact of dialysis modality or dose per se on out- a difference in mortality, with the observed mortality
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being similar in both groups. This suggests that the im- mortality were not different between the two groups, sug-
gesting a consistent effect of ARF. However, predictedpact of ARF on survival, at least as we have defined it,
is relatively constant. The study of Brivet et al [7] de- outcomes were remarkably different. For patients with
ARF at ICU admission (early ARF, Table 5), APACHEscribed a population with more severe renal failure, as
their definition required a considerably larger change in III performed very well, as reflected by a standardized
mortality near 1. For patients who developed ARF subse-function than did ours, and this difference may explain
the fact that we could not reproduce their finding. It is quent to initial scoring, standardized mortality was dou-
bled and there was a significant difference between ob-entirely possible, certainly it seems intuitively likely, that
the development of severe ARF following admission has served and predicted mortality. Admission APACHE III
scores did not predict subsequent organ failure nor thethe negative impact described by Brivet et al [7]. Another
study examined the impact of the development of organ impact of this failure on outcome. Admission APACHE
III scores thus performed very well for patients with nofailure after ICU admission on outcome in 287 patients
with sepsis syndrome [18]. In this highly selected group renal failure and ARF patients with established dysfunc-
tion at entry, but less well with patients who developedof ICU patients, renal dysfunction developing after the
onset of sepsis carried a higher risk of death than the ARF later. It is interesting to speculate that whatever
other conditions non-renal failure patients may developinitial development of acute respiratory failure. Simi-
larly, development of cardiovascular, neurologic, or he- in the ICU, they do no appear to interfere with the ability
of APACHE III to predict outcome. The data frompatic dysfunction also carried a worse prognosis when
stratified for admission APACHE III score. Russell et al suggest that this may be the case [18]. The
subsequent development of ARF, even with our excep-A previous retrospective analysis of established paren-
chymal ARF at this institution suggested that ARF out- tionally broad definition, does skew predictive value.
This observation also argues that acute renal dysfunctioncome might be better in recipients of organ transplants
than that described in other ICU patients [17]. It was also is a particularly sensitive prognostic index.
The relatively small number of ESRD and transplantnoted that the relation between survival and APACHE
II scores appeared to be altered by transplantation. Since recipients in our study does not permit firm conclusions
regarding APACHE III predictive value in these groups.there are a large number of transplants performed at
our institution, we separately examined the outcomes of APACHE III tended to over-predict mortality for ESRD
patients, and it is our speculation that this is because ittransplanted patients in the ICU with ARF, ESRD, or no
renal failure. As with non-transplant patients, the trans- does not discriminate well between ARF and ESRD
processes. APACHE III appears to predict outcome inplant recipients with ARF had higher APACHE III
scores, longer ICU length of stay, and higher mortality transplant patients with ARF somewhat better than in
non-transplant patients, with a standardized mortalitythat transplant recipients with no renal failure. Trans-
plant patients with ESRD, although having quite high close to 1.
We have applied a standard criterion for all-cause ARFAPACHE III scores, had ICU length of stay and mortal-
ity similar to that seen with patients with no renal failure. to an ICU population. Our study demonstrates that ARF
is quite common in the ICU and appears to magnify mor-Actual mortality tended to be lower in transplant pa-
tients than in non-transplant patients, but the differences tality regardless of whether the ARF is severe enough
to require dialysis. This effect is further magnified indid not reach statistical significance. The data do not
permit us to extend the observation of lower mortality patients with ARF severe enough to require dialysis. A
unique feature of our study is the evaluation of criticallyfor ARF in transplant patients using the current defini-
tion of ARF. ill patients with ESRD requiring dialysis. These repre-
sent a group of patients who have not developed theICU mortality, as predicted by APACHE III, appears
to be well suited for non-renal failure patients. Observed physiology of ARF but who nonetheless have no renal
function. ESRD patients requiring dialysis have out-and predicted mortalities for non-renal failure patients
agreed well over the whole range of APACHE scores comes associated with an increase in mortality of about
5 to 6%, or roughly a doubling compared to patients(Fig. 1). APACHE III appeared to under-predict mor-
tality in ARF patients, as suggested by a standardized with no renal failure. This may represent the increment
in morality attributable to loss of organ function. Thatmortality in excess of unity. When the relation between
observed and predicted mortality for ARF patients was increment associated with manifesting ARF, with or
without need for dialysis, appears to be considerablyexamined over the whole range of APACHE scores
(Fig. 2), under-predicting occurred at the low end of greater (Fig. 5). Our present data do not allow us to
identify the specific attributable mortality of ARF alone.APACHE scores, between 50 and 80. To examine this
further, we grouped ARF patients into those with and APACHE III appears to be a very good prognostic tool
for patients with no renal failure or with ARF at ICUwithout ARF at the time of initial APACHE III scoring.
Actual outcomes in terms of ICU length of stay and admission. The development of ARF in the ICU after
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